![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-desktop-headergif-72716.gif)
![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-mob-headergif-95876.gif)
API Suppliers
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
EU WC
0
Listed Suppliers
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
0
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
1. 66898-62-2
2. Somalgen
3. Lomucin
4. Talniflumato
5. Ba 7602-06
6. Ba-7602-06
7. Phthalidyl 2-(3-trifluoromethylanilino)nicotinate
8. Ba7602-06; Somalgen
9. Jfk78s0u9s
10. [(1r)-3-oxo-1h-2-benzofuran-1-yl] 2-[3-(trifluoromethyl)anilino]pyridine-3-carboxylate
11. 3-phthalidyl Ester Of 2-((3-(trifluoromethyl)phenyl)amino)-3-pyridinecarboxylic Acid
12. Ncgc00167754-01
13. 3-ftalidilico Del Acido 2-((3-(trifluormetil)fenil)amino)-3-piridincarboxilico
14. (3-oxo-1h-2-benzofuran-1-yl) 2-[3-(trifluoromethyl)anilino]pyridine-3-carboxylate
15. Dsstox_cid_26740
16. Dsstox_rid_81869
17. Dsstox_gsid_46740
18. 2-[[3-(trifluoromethyl)phenyl]amino]-3-pyridinecarboxylic Acid 1,3-dihydro-3-oxo-1-isobenzofuranyl Ester
19. Talniflumatum
20. Talniflumate [usan:inn]
21. Talniflumatum [inn-latin]
22. Talniflumato [inn-spanish]
23. 3-pyridinecarboxylic Acid, 2-((3-(trifluoromethyl)phenyl)amino)-, 1,3-dihydro-3-oxo-1-isobenzofuranyl Ester
24. Cas-66898-62-2
25. Unii-jfk78s0u9s
26. Brn 0503261
27. Somalgen (tn)
28. 3-pyridinecarboxylic Acid, 2-[[3-(trifluoromethyl)phenyl]amino]-, 1,3-dihydro-3-oxo-1-isobenzofuranyl Ester
29. Phthalidyl 2-(alpha,alpha,alpha-trifluoro-m-toluidino)nicotinate
30. Talniflumate [mi]
31. Talniflumate (usan/inn)
32. Talniflumate [inn]
33. 2-(alpha,alpha,alpha-trifluoro-m-toluidino)nicotinic Acid Phthalidyl Ester
34. Talniflumate [usan]
35. 3-ftalidilico Del Acido 2-((3-(trifluormetil)fenil)amino)-3-piridincarboxilico [spanish]
36. Schembl23691
37. Talniflumate [mart.]
38. Talniflumate [who-dd]
39. Chembl1081506
40. Dtxsid3046740
41. Chebi:91991
42. Hms3269m13
43. Hms3413d19
44. Hms3677d19
45. Msi-1995
46. Phthalidyl 2-(alpha,alpha,alpha,-trifluoro-m-toluidino)nicotinate
47. Tox21_112584
48. Mfcd00866135
49. S6439
50. Akos015895754
51. Tox21_112584_1
52. Db09295
53. Ks-5130
54. Nicotinic Acid, 2-(alpha,alpha,alpha-trifluoro-m-toluidino)-, Phthalidyl Ester
55. Ncgc00167754-02
56. Ac-14144
57. Db-054972
58. Hy-103370
59. Cs-0027765
60. Ft-0630769
61. T3101
62. D02701
63. T72807
64. 898t622
65. A835581
66. Brd-a98378129-001-01-4
67. Q22075910
68. Phthalidyl 2-(3'-trifluormethylanilino)-pyridin-3-carboxylate
69. Phthalidyl 2-(3-trifluoromethylanilino)-3-pyridinecarboxylate
70. Phthalidyl 2-(.alpha.,.alpha.,.alpha.-trifluoro-m-toluidino)nicotinate
71. 2-(.alpha.,.alpha.,.alpha.-trifluoro-m-toluidino)nicotinic Acid Phthalidyl Ester
72. 3-oxo-1,3-dihydroisobenzofuran-1-yl 2-(3-(trifluoromethyl)phenylamino)nicotinate
73. Nicotinic Acid, 2-(.alpha.,.alpha.,.alpha.-trifluoro-m-toluidino)-, Phthalidyl Ester
74. (3-oxo-1h-isobenzofuran-1-yl) 2-[3-(trifluoromethyl)anilino]pyridine-3-carboxylate;talniflumate
75. 2-[[3-(trifluoromethyl)phenyl]amino]-1,3-dihydro-3-oxo-1-isobenzofuranyl 3-pyridinecarboxylic Acid Ester
76. 2-[3-(trifluoromethyl)anilino]-3-pyridinecarboxylic Acid (3-oxo-1h-isobenzofuran-1-yl) Ester
Molecular Weight | 414.3 g/mol |
---|---|
Molecular Formula | C21H13F3N2O4 |
XLogP3 | 5.3 |
Hydrogen Bond Donor Count | 1 |
Hydrogen Bond Acceptor Count | 9 |
Rotatable Bond Count | 5 |
Exact Mass | 414.08274139 g/mol |
Monoisotopic Mass | 414.08274139 g/mol |
Topological Polar Surface Area | 77.5 Ų |
Heavy Atom Count | 30 |
Formal Charge | 0 |
Complexity | 644 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 0 |
Undefined Atom Stereocenter Count | 1 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 1 |
Talnifumate is a phthalidyl ester of nifumic acid, which has potent analgesic and anti-inflammatory effects and is widely used to treat inflammatory disorders, such as rheumatoid arthritis and osteoarthritis, and has also been studied for the management of cystic fibrosis.
Talniflumate is metabolized to its prodrug, niflumic acid, which has several pharmacodynamic effects. Firstly, it blocks synthesis of mucin. Secondly, talniflumate blocks prostaglandin synthesis by cyclooxygenases, which aids in pain and inflammation management.
Volume of Distribution
In 12 subjects after a single oral administration, total plasma clearance of the main metabolite, niflumic acid, averaged 45 ml/min giving a distribution volume of 0.12 l/kg on average.
Clearance
This drug undergoes extensive first pass effect.
Extensive liver metabolism.
Approximately 2h in 12 subjects
Talniflumate is a strong and selective inhibitor of core mucin-synthesizing enzyme GCNT3 (core 2 b-1,6 N-acetylglucosaminyltransferase). Talniflumate decreases gene expression of GCNT3 and production of mucins in vivo and in vitro. Talniflumate improves response of pancreatic tumors to gefitinib (chemotherapy drug). Talniflumate is a strong calcium-activated chloride channel (CaCC) blocker.